Data from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can potentially ameliorate ineffective hematopoiesis and address cytopenias, and also provide broader ...
Antengene Corporation Limited Antengene SEHK 6996HK a leading innovative commercial-stage global biopharmaceutical company dedicated to discovering developing and commercializing first-in-class andor ...
Odronextamab monotherapy led to complete responses in all patients with previously untreated follicular lymphoma evaluable for efficacy, per ...
Southlake Regional Health Centre’s Dr. Kevin Teoh is a leading cardiac surgeon. He implanted the first Perceval valve in ...
AFM28, a bispecific, tetravalent innate cell engager (ICE ®) targeting CD123 and CD16A, achieved a 40% composite complete ...
Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced initial data from its ongoing Phase 1b study evaluating R2891, ...
Patients with newly diagnosed multiple myeloma experienced robust clinical activity when treated with Tecvayli (teclistamab) ...
The progression-free survival (PFS) rate at 5 years improved from 40.8% with active monitoring and no disease-specific ...
The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with ...
Bionomics (BNOX) announced that the results from its Phase 2 ATTUNE study have been published in the NEJM Evidence. The data were also ...
New genetic medicines for sickle cell disease were hailed as a milestone. Now researchers are working on ways to widen access ...
Kura Oncology, Inc. (Nasdaq: KURA, "Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin”) provided encouraging cli ...